Medicenna Therapeutics Corp (MDNA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medicenna Therapeutics Corp (MDNA) has a cash flow conversion efficiency ratio of -0.799x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-4.96 Million ≈ $-3.59 Million USD) by net assets (CA$6.21 Million ≈ $4.49 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Medicenna Therapeutics Corp (MDNA) defensive interval to measure how many days the company can operate on defensive assets alone.
Medicenna Therapeutics Corp - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Medicenna Therapeutics Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Medicenna Therapeutics Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medicenna Therapeutics Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hotel Royal Chihpen
TWO:5704
|
0.032x |
|
P&H Tech Co. Ltd.
KQ:239890
|
0.059x |
|
Derwent London PLC
LSE:DLN
|
0.047x |
|
Murray International Trust
LSE:MYI
|
0.025x |
|
Pusan Cast Iron Co., Ltd.
KO:005030
|
0.020x |
|
Pudjiadi & Sons Tbk
JK:PNSE
|
0.115x |
|
Hakers Enterprise Co Ltd
TWO:4432
|
0.032x |
|
Compagnie de Chemins de Fer Départementaux Société Anonyme
PA:MLCFD
|
N/A |
Annual Cash Flow Conversion Efficiency for Medicenna Therapeutics Corp (2014–2025)
The table below shows the annual cash flow conversion efficiency of Medicenna Therapeutics Corp from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see MDNA market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | CA$19.09 Million ≈ $13.81 Million |
CA$-16.49 Million ≈ $-11.93 Million |
-0.864x | +72.43% |
| 2024-03-31 | CA$5.19 Million ≈ $3.76 Million |
CA$-16.26 Million ≈ $-11.76 Million |
-3.132x | -629.72% |
| 2023-03-31 | CA$29.49 Million ≈ $21.33 Million |
CA$-12.66 Million ≈ $-9.16 Million |
-0.429x | +62.08% |
| 2022-03-31 | CA$20.84 Million ≈ $15.07 Million |
CA$-23.58 Million ≈ $-17.06 Million |
-1.132x | -182.01% |
| 2021-03-31 | CA$38.15 Million ≈ $27.59 Million |
CA$-15.31 Million ≈ $-11.08 Million |
-0.401x | -62.04% |
| 2020-03-31 | CA$36.15 Million ≈ $26.15 Million |
CA$-8.95 Million ≈ $-6.48 Million |
-0.248x | +91.94% |
| 2019-03-31 | CA$2.62 Million ≈ $1.89 Million |
CA$-8.04 Million ≈ $-5.81 Million |
-3.072x | +34.41% |
| 2018-03-31 | CA$2.16 Million ≈ $1.56 Million |
CA$-10.12 Million ≈ $-7.32 Million |
-4.683x | -326.75% |
| 2017-03-31 | CA$6.66 Million ≈ $4.82 Million |
CA$-7.31 Million ≈ $-5.28 Million |
-1.097x | +4.17% |
| 2016-03-31 | CA$2.24 Million ≈ $1.62 Million |
CA$-2.57 Million ≈ $-1.86 Million |
-1.145x | -102.51% |
| 2015-03-31 | CA$-19.30K ≈ $-13.96K |
CA$-880.32K ≈ $-636.81K |
45.603x | +1865.98% |
| 2014-03-31 | CA$-267.05K ≈ $-193.18K |
CA$-619.44K ≈ $-448.09K |
2.320x | -- |
About Medicenna Therapeutics Corp
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleuk… Read more